Last updated: September 23, 2026
DAYVIGO, the brand name for lemborexant, is Eisai’s dual orexin receptor antagonist for adult insomnia. The product has expanded in the United States and Japan, but its commercial trajectory is constrained by a crowded sleep-medicine market, controlled-substance prescribing requirements, payer pressure, and competition from BELSOMRA and QUVIVIQ.
Eisai does not report DAYVIGO as a separate global profit-and-loss line. Public disclosures indicate strong sales growth from a small launch base, with Japan and the United States representing the principal commercial markets. The product’s market opportunity remains material, but it is unlikely to approach the scale of Eisai’s Alzheimer’s portfolio.
What is DAYVIGO and how does it work?
DAYVIGO contains lemborexant, a small-molecule antagonist of the orexin OX1 and OX2 receptors. The FDA approved 5-mg and 10-mg tablets on Dec. 20, 2019, for the treatment of insomnia characterized by difficulties with sleep onset or sleep maintenance in adults.[1]
Lemborexant differs from zolpidem, eszopiclone and benzodiazepines because it targets the orexin wake-regulation system rather than the gamma-aminobutyric acid pathway. The clinical positioning is based on improving sleep initiation and maintenance while avoiding the pharmacology of traditional sedative-hypnotics.
The principal product attributes are:
| Item |
DAYVIGO |
| Active ingredient |
Lemborexant |
| Manufacturer |
Eisai Co., Ltd. |
| Initial FDA approval |
Dec. 20, 2019 |
| Strengths |
5 mg and 10 mg |
| Dosage form |
Oral tablet |
| U.S. indication |
Adult insomnia |
| U.S. controlled-substance status |
Schedule IV |
| Primary mechanism |
Dual OX1/OX2 receptor antagonism |
| Main branded competitors |
BELSOMRA, QUVIVIQ |
| Main unbranded competitors |
Zolpidem, eszopiclone, zaleplon, benzodiazepines, OTC sleep products |
When did DAYVIGO launch and how has adoption developed?
DAYVIGO launched in Japan in 2020 and in the United States during the same year. Eisai has promoted the medicine as an alternative for patients who have difficulty falling asleep, staying asleep, or both.
Adoption has been supported by several factors:
- Insomnia is prevalent, chronic and frequently undertreated.
- Many patients and physicians seek alternatives to benzodiazepines and Z-drugs.
- Lemborexant demonstrated activity across sleep-onset and sleep-maintenance measures.
- The product is available in two strengths, allowing dose adjustment.
- Orexin antagonists have created a distinct branded segment within prescription insomnia treatment.
Adoption has also faced barriers. DAYVIGO is a controlled substance in the United States, can cause next-day impairment and somnolence, and carries warnings concerning complex sleep behaviors and central nervous system depressants.[2] Physicians may also begin treatment with lower-cost generic products before prescribing an orexin antagonist.
What is the financial trajectory for DAYVIGO?
Eisai’s public reporting indicates that DAYVIGO sales have grown steadily from launch levels. The company reports product sales by major products and regions rather than a fully transparent worldwide DAYVIGO income statement.
Publicly disclosed company materials place DAYVIGO annual sales in the tens of billions of yen, with sales growth continuing after launch. Eisai has identified DAYVIGO as a growth product within its neurology and sleep portfolio, although the product remains substantially smaller than LEQEMBI and the company’s established oncology products.[3]
| Financial driver |
Effect on DAYVIGO |
| Japanese prescription growth |
Positive |
| U.S. formulary access |
Positive but variable |
| Orexin-antagonist awareness |
Positive |
| Generic zolpidem pricing |
Negative |
| QUVIVIQ competition |
Negative |
| Schedule IV controls |
Negative |
| Long-term insomnia treatment |
Positive |
| Limited direct-to-consumer scale |
Negative |
| Eisai’s established commercial infrastructure |
Positive |
The financial profile is likely to remain a growth-to-maturity trajectory rather than a rapid blockbuster curve. The addressable population is large, but branded insomnia products compete against inexpensive generics and over-the-counter products. Reimbursement and physician familiarity are more important than disease prevalence alone.
Eisai has not disclosed a material DAYVIGO-related impairment, withdrawal or commercialization restructuring. That supports continued investment in the product, but it does not establish that DAYVIGO has reached peak profitability.
How does DAYVIGO compare with BELSOMRA and QUVIVIQ?
DAYVIGO competes directly with BELSOMRA and QUVIVIQ, the other branded orexin receptor antagonists. The competitive distinction is based on receptor profile, clinical data, launch timing, price, formulary placement and prescriber familiarity.
| Product |
Active ingredient |
Company |
FDA approval |
Competitive position |
| DAYVIGO |
Lemborexant |
Eisai |
2019 |
Earlier entrant with sleep-onset and maintenance positioning |
| BELSOMRA |
Suvorexant |
Merck |
2014 |
First FDA-approved orexin antagonist; established brand |
| QUVIVIQ |
Daridorexant |
Idorsia/Jazz |
2022 |
Newer entrant with short half-life positioning |
| Ambien and generics |
Zolpidem |
Multiple |
1992 |
Low-cost, high-volume generic standard |
| Lunesta and generics |
Eszopiclone |
Multiple |
2004 |
Established generic alternative |
BELSOMRA benefits from earlier market entry and physician familiarity. DAYVIGO benefits from a more recent evidence base and an established Eisai commercial organization. QUVIVIQ has emphasized next-day functioning and pharmacokinetic characteristics, creating differentiation within the orexin category.
The main commercial question is whether orexin antagonists expand the overall branded insomnia market or mainly displace one another. Current evidence supports both effects. Some patients switch from generic sedative-hypnotics, but branded products also compete for the same commercially attractive patients.
What is the FDA regulatory status of DAYVIGO?
DAYVIGO is FDA-approved for adults with insomnia. The FDA label recommends an initial dose of 5 mg, with an increase to 10 mg when clinically appropriate. The label includes warnings related to central nervous system depression, next-day impairment, sleep paralysis, hallucinations, cataplexy-like symptoms and complex sleep behaviors.[1]
The product is a Schedule IV controlled substance under the federal Controlled Substances Act. This status creates prescribing and dispensing requirements that do not apply to many noncontrolled sleep aids.
DAYVIGO is not a biologic. Biosimilar risk is therefore irrelevant. The relevant regulatory threat is an abbreviated new drug application, or ANDA, for a chemically equivalent generic version.
What patents protect DAYVIGO?
DAYVIGO is protected by a combination of compound, formulation, pharmaceutical-composition and potentially method-of-use rights. The commercially relevant patent estate is broader than the five-year new chemical entity exclusivity period.
The core protection categories are:
Compound patents
Compound claims cover lemborexant and related chemical structures. These patents generally provide the earliest and most important protection, but their term depends on the earliest effective nonprovisional priority date and any patent-term adjustment.
Formulation and pharmaceutical-composition patents
Formulation rights may cover tablet compositions, solid forms, crystalline forms, particle characteristics, excipients or manufacturing processes. These patents can create later-expiring barriers even after basic compound protection has expired.
Method-of-use patents
Method patents may cover treatment of insomnia, sleep-onset difficulty, sleep-maintenance difficulty, dosing regimens, patient populations or administration schedules. Their value depends on whether the patented use is listed in the FDA Orange Book and whether generic labeling can omit the protected indication.
Regulatory exclusivity
DAYVIGO received five years of new chemical entity exclusivity beginning with FDA approval on Dec. 20, 2019. That period generally expired on Dec. 20, 2024. NCE exclusivity barred submission of an ANDA for four years, making Dec. 20, 2023 the earliest ordinary date for a Paragraph IV ANDA submission, subject to statutory and patent conditions.[4]
Patent protection can continue after regulatory exclusivity ends.
What is the Orange Book status of DAYVIGO?
DAYVIGO is an FDA-approved small-molecule prescription product subject to Orange Book patent-listing rules. The Orange Book is the controlling source for current listed patents, expiration dates, pediatric extensions and exclusivity codes.[4]
The commercial exposure is not determined solely by whether DAYVIGO has an Orange Book listing. A generic applicant can:
- Certify that listed patents have expired.
- Certify that listed patents will expire on a specified date.
- File a Paragraph IV certification alleging that a listed patent is invalid, unenforceable or not infringed.
- Submit a section viii statement and omit a protected method of use when the law permits.
- Challenge patents that are not listed in the Orange Book through separate litigation or regulatory strategies.
Because patent listings, delistings and expiration calculations can change, the relevant legal analysis must distinguish the FDA-listed patents from broader Eisai patent rights that may not block an ANDA directly.
When could generic DAYVIGO enter the U.S. market?
The earliest practical generic-entry date depends on three factors:
- The status of Orange Book-listed patents.
- The outcome of any Paragraph IV litigation.
- The timing of ANDA approval and any 180-day first-filer exclusivity.
The five-year NCE period does not by itself determine the launch date. It expired in December 2024, but a generic may still be blocked by valid, unexpired patents.
A generic launch could occur under several scenarios:
| Scenario |
Commercial result |
| No ANDA challenge |
Entry waits for patent expiry or settlement date |
| Paragraph IV challenge with no litigation |
Potential approval after FDA review and statutory timing |
| Litigation filed within 45 days |
Approval may be stayed for up to 30 months, subject to court and FDA rules |
| Successful invalidity or noninfringement case |
Earlier generic launch possible |
| Settlement with licensed entry |
Entry occurs on an agreed date, often before patent expiry |
| At-risk launch |
Generic enters before final resolution and faces damages or injunction risk |
No widely reported U.S. DAYVIGO Paragraph IV settlement or definitive generic launch has been publicly established in the principal company and regulatory disclosures reviewed for this analysis.
What patent litigation affects DAYVIGO?
No major, publicly reported U.S. patent litigation has become a central commercial event for DAYVIGO comparable to the high-profile litigation surrounding major oncology, diabetes or immunology products.
The absence of a prominent litigation record does not eliminate generic risk. It may reflect the product’s current sales level, the timing of ANDA activity, the economics of challenging the product or confidential negotiations.
The key litigation risks are likely to involve:
- Validity of the core compound patent.
- Written-description and enablement arguments.
- Obviousness challenges based on orexin-receptor literature.
- Infringement of formulation or solid-form patents.
- Carve-out strategies for insomnia indications.
- Patent-term calculations and Orange Book listing disputes.
Are there DAYVIGO licensing deals?
Eisai has retained the principal development and commercial rights to DAYVIGO in its core markets. No major global out-license or co-promotion transaction has defined the product’s commercial trajectory.
The absence of a major licensing transaction means Eisai retains the upside from sales growth but also bears launch, reimbursement, medical-affairs and litigation costs. Regional distribution or commercialization arrangements do not necessarily indicate a transfer of core intellectual-property ownership.
How strong is the DAYVIGO patent estate?
The DAYVIGO patent estate is commercially meaningful but should be considered moderate rather than unassailable.
Its strengths are:
- A differentiated active ingredient.
- FDA approval for a chronic, recurring condition.
- Multiple potential protection layers.
- A branded market with high patient turnover and recurring prescriptions.
- Eisai’s ability to defend a strategic neurology product.
Its weaknesses are:
- The core product is a small molecule vulnerable to ANDA litigation.
- NCE exclusivity has expired.
- Insomnia generics are inexpensive and entrenched.
- Method-of-use patents may be vulnerable to label carve-outs.
- Formulation patents may not prevent all generic competition.
- The product’s revenue base may limit the economic rationale for prolonged litigation.
The strongest protection is usually the valid, enforceable compound patent. Formulation and method patents can extend commercial protection, but their ability to delay generic entry depends on claim scope, Orange Book listing and the generic applicant’s proposed label.
What geographic markets drive DAYVIGO revenue?
Japan and the United States are the principal markets associated with DAYVIGO. Japan has provided a favorable commercial base because Eisai has established neurology and prescription-drug infrastructure. The United States provides greater revenue potential but has more pronounced payer, controlled-substance and generic-substitution pressures.
DAYVIGO’s geographic risk is concentrated in the United States because a successful generic launch could rapidly reduce net price and volume. Japan may experience a slower erosion curve, depending on reimbursement policy, local generic timing and physician prescribing behavior.
What generic and competitive risks exist for DAYVIGO?
The main risks are:
- Generic lemborexant after patent barriers weaken.
- Continued low-cost substitution by zolpidem and eszopiclone.
- BELSOMRA’s established prescriber base.
- QUVIVIQ’s newer product positioning.
- Payer restrictions requiring generic failure before branded coverage.
- Controlled-substance concerns affecting primary-care prescribing.
- Safety concerns related to next-day impairment.
- Limited evidence that branded orexin antagonists can sustain premium pricing over the long term.
A generic launch would probably produce a rapid reduction in U.S. net price, followed by volume migration. The erosion rate would depend on the number of approved ANDAs, the presence of an authorized generic and the strength of any settlement restrictions.
Key Takeaways
- DAYVIGO is Eisai’s lemborexant-based dual orexin receptor antagonist for adult insomnia.
- FDA approval occurred on Dec. 20, 2019, with 5-mg and 10-mg tablets.
- NCE exclusivity expired in December 2024, but patent barriers may continue beyond that date.
- Japan and the United States are the principal commercial markets.
- Eisai has reported sustained sales growth, but does not publish a fully separate global DAYVIGO profit-and-loss statement.
- BELSOMRA, QUVIVIQ and low-cost generic hypnotics define the competitive set.
- Biosimilar risk does not apply because DAYVIGO is a small molecule.
- Generic risk depends on Orange Book patents, Paragraph IV activity, litigation and any settlement-based launch date.
- The patent estate is meaningful but exposed to standard small-molecule validity, infringement and label-carve-out challenges.
- The product’s long-term value depends more on sustained branded pricing and market share than on category expansion alone.
FAQs About DAYVIGO Market and Patent Risk
Is DAYVIGO a biologic or a small-molecule drug?
DAYVIGO is a small-molecule drug containing lemborexant. Generic competition would proceed through the ANDA pathway, not the biosimilar pathway.
Does DAYVIGO have pediatric exclusivity?
The FDA Orange Book is the controlling source for any pediatric-exclusivity code or six-month extension. Pediatric exclusivity cannot be assumed from the product’s adult approval or clinical-development history.
Is DAYVIGO stronger than BELSOMRA?
DAYVIGO has a later-generation evidence base and competes on sleep-onset and sleep-maintenance efficacy. BELSOMRA benefits from earlier approval and longer market familiarity. Neither product has a universal clinical advantage for every insomnia patient.
Can a generic copy only the 5-mg DAYVIGO tablet?
An ANDA applicant may seek approval for one or both strengths, subject to bioequivalence, patent certifications and FDA requirements. A single-strength launch could precede broader generic availability.
What would most reduce DAYVIGO’s revenue?
A successful U.S. generic launch would likely have the largest immediate effect. Before generic entry, formulary exclusion, QUVIVIQ adoption, BELSOMRA price competition and expanded use of low-cost generic hypnotics are the principal revenue pressures.
References
- U.S. Food and Drug Administration. (2019). DAYVIGO (lemborexant) prescribing information.
- U.S. Food and Drug Administration. (2019). FDA approves new treatment for insomnia, DAYVIGO.
- Eisai Co., Ltd. (2024). Consolidated financial results and annual report.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
